Repligen Corporation

Equities

RGEN

US7599161095

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 16:00:00 2024-06-14 EDT 5-day change 1st Jan Change
125.6 USD -0.25% Intraday chart for Repligen Corporation -13.83% -30.13%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday MT
Repligen Names Olivier Loeillot CEO; Tony Hunt to Become Executive Chair MT
Repligen Corporation Announces Management Changes, Effective September 1, 2024 CI
Repligen Corporation Announces CEO Changes, Effective September 1, 2024 CI
Transcript : Repligen Corporation Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 11:30 AM
Transcript : Repligen Corporation Presents at The 44th Annual William Blair Growth Stock Conference, Jun-05-2024 12:00 PM
Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing CI
Transcript : Repligen Corporation Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-30-2024 08:40 AM
Repligen Insider Sold Shares Worth $3,377,283, According to a Recent SEC Filing MT
Transcript : Repligen Corporation Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-14-2024 10:30 AM
UBS Adjusts Price Target on Repligen to $205 From $225, Maintains Buy Rating MT
Repligen's Q1 Adjusted Earnings, Revenue Fall MT
Transcript : Repligen Corporation, Q1 2024 Earnings Call, May 01, 2024
(RGEN) REPLIGEN CORPORATION Sees Fiscal Year 2024 EPS Range $1.42 - $1.49 MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Posts Q1 Revenue $151.3M, vs. Street Est of $150.1M MT
Earnings Flash (RGEN) REPLIGEN CORPORATION Posts Adjusted Q1 EPS $0.28, vs. Street Est of $0.30 MT
Repligen Corporation Provides Earnings Guidance for the Fiscal Year 2024 CI
Repligen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
North American Morning Briefing : Traders Wait for -2- DJ
RBC Cuts Price Target on Repligen to $221 From $225, Keeps Outperform Rating MT
Transcript : Repligen Corporation Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-20-2024 03:00 PM
Repligen Corporation Appoints Maggie A. Pax as Board of Directors CI
Repligen Insider Sold Shares Worth $681,348, According to a Recent SEC Filing MT
Repligen Insider Sold Shares Worth $3,298,632, According to a Recent SEC Filing MT
Repligen Insider Sold Shares Worth $866,204, According to a Recent SEC Filing MT
Chart Repligen Corporation
More charts
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
125.6 USD
Average target price
203.7 USD
Spread / Average Target
+62.16%
Consensus
  1. Stock Market
  2. Equities
  3. RGEN Stock
  4. News Repligen Corporation
  5. Repligen Insider Sold Shares Worth $3,377,283, According to a Recent SEC Filing